4MTx is a biotech developing best-in-class drugs that target key pathways in neural plasticity – the ability of the brain to form new cells and connections. Plasticity is impaired in a range of disorders including bipolar disorder and Alzheimer’s disease. 4MTx team members have co-founded public companies including Fate Therapeutics and Cytokinetics. Our CEO, Pablo Lapuerta, has over 25 years of biotech experience and a record of successful drug approvals. Don Hayden, 4MTx Chairperson, was President of Global Pharmaceuticals at Bristol Myers-Squibb and served as chairperson of several companies. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium and esketamine enhance neural plasticity in living human brain cells – and then to design better alternatives. Our lead 4MT2001 is intended to provide the benefits of lithium in bipolar disorder with better safety. It is the major metabolite of a drug that has previously demonstrated animal and human safety. We plan to initiate a clinical trial for 4MT2001 in 2024. We will first seek approval for acute bipolar mania, where short-term studies are feasible and sufficient to show efficacy. Our pipeline also includes 4MT-01, offering even greater potency and selectivity targeting the lithium response pathway. Our 4MT-03 program targets a pathway involved in esketamine’s beneficial effects.